RITALIN
Clinical safety rating
cautionComprehensive clinical and safety monograph for RITALIN (RITALIN).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), increasing their synaptic concentrations.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to the inactive metabolite ritalinic acid. Minor pathways include hydroxylation and oxidative metabolism. CYP2D6 plays a minor role. |
| Excretion | Renal: 80-90% (as unchanged drug and metabolites, primarily ritalinic acid); Fecal: <1%; Biliary: minimal |
| Half-life | 3-4 hours (immediate-release); 6-8 hours (sustained-release); clinical context: requires multiple daily dosing for sustained effect |
| Protein binding | 10-33% bound to albumin and α₁-acid glycoprotein |
| Volume of Distribution | 0.2-0.5 L/kg (low Vd, reflects limited tissue distribution) |
| Bioavailability | Oral: 20-30% (due to first-pass metabolism); Intravenous: 100% |
| Onset of Action | Oral immediate-release: 20-30 minutes; Oral sustained-release: 1-2 hours; Intravenous: <5 minutes |
| Duration of Action | Immediate-release: 3-4 hours; Sustained-release: 8-12 hours; clinical notes: shorter duration with immediate-release may require multiple doses |
| Molecular Weight | 329.39 |
Initial: 5 mg orally twice daily (before breakfast and lunch); increase by 5-10 mg weekly; maximum 60 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Children ≥6 years: initial 5 mg orally twice daily; increase by 5 mg weekly; max 60 mg/day; <6 years: not recommended. |
| Geriatric use | Start at 2.5 mg twice daily; increase slowly; monitor for hypertension, insomnia, and agitation. |
| 1st trimester | Limited data; animal studies show increased risk of malformations at high doses. Use only if benefit outweighs risk. Consider non-pharmacologic alternatives. |
| 2nd trimester | Monitor fetal growth; potential for decreased appetite and weight gain in mother, affecting fetal nutrition. Use with caution. |
| 3rd trimester | Neonatal adverse effects reported: jitteriness, irritability, poor feeding. Avoid use in late pregnancy unless essential. |
Clinical note
Comprehensive clinical and safety monograph for RITALIN (RITALIN).
| Placental transfer | Methylphenidate crosses the placenta; animal studies show transfer, but human data limited. Pharmacokinetic studies indicate rapid transfer with fetal exposure approximately 30-50% of maternal plasma levels. |
| Breastfeeding | Ritalin (methylphenidate) is excreted into breast milk in low amounts (relative infant dose ~0.2-0.7%). Monitor infant for agitation, insomnia, and poor weight gain. Avoid in breastfeeding if possible; if used, prescribe immediate-release to minimize exposure. |
| Lactation Rating | L2 (Safer), but consider L3 if high doses or prolonged use. |
| Teratogenic Risk | First trimester: Limited human data; animal studies at high doses show increased risk of malformations (e.g., orofacial clefts, neural tube defects). Second and third trimesters: Potential for increased risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, tachycardia, poor feeding). A causal relationship in humans has not been definitively established; risk-benefit assessment is essential. |
| Fetal Monitoring | Maternal: Baseline and periodic monitoring of heart rate, blood pressure, and weight; assessment for signs of abuse or dependence; fetal: serial ultrasound for growth restriction if used chronically; neonatal monitoring for withdrawal symptoms (e.g., irritability, hypertonia, poor feeding) for 48-72 hours postpartum. |
| Fertility Effects | In animal studies, high doses of methylphenidate have been associated with reduced fertility and increased postimplantation loss in females; in males, decreased sperm motility and concentration have been reported. Human data are insufficient to determine effects on fertility; however, caution is advised in patients attempting conception. |
■ FDA Black Box Warning
Methylphenidate has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
Marked anxiety, tension, or agitationGlaucomaHypersensitivity to methylphenidate or any excipientConcomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuationTics or Tourette's syndrome (may exacerbate)
| Precautions | Risk of serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems, Increased blood pressure and heart rate, Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, and aggression, Potential for growth suppression in children; monitor height and weight, Risk of priapism, May lower seizure threshold, Peripheral vasculopathy including Raynaud's phenomenon |
| Food/Dietary | Avoid excessive caffeine (coffee, tea, energy drinks) as it may exacerbate stimulant effects like nervousness and insomnia. Food does not significantly alter absorption of immediate-release forms; take 30-45 minutes before meals for optimal effect. For extended-release (Ritalin LA), avoid high-fat meals as they may delay absorption and reduce peak concentration. |
| Clinical Pearls | Methylphenidate (Ritalin) is a first-line pharmacotherapy for ADHD. Onset of action is rapid (20-30 min for immediate-release). Monitor for appetite suppression, insomnia, and growth deceleration. Avoid in patients with severe anxiety, glaucoma, or tic disorders. May lower seizure threshold. Use with caution in hypertension; monitor BP and heart rate. Abuse potential exists; schedule II controlled substance. For extended-release formulations, instruct not to crush or chew. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Swallow extended-release capsules whole; do not crush or chew. · Avoid taking in the evening to prevent insomnia. · Report any chest pain, palpitations, or shortness of breath immediately. · This medication can be habit-forming; avoid sharing with others. · Common side effects include decreased appetite, trouble sleeping, and headache. · Regular blood pressure and heart rate monitoring may be needed. · Notify your doctor if you develop tics or worsening anxiety. |
Loading safety data…